262 related articles for article (PubMed ID: 27141054)
1. Fibroblast Growth Factor Receptor-Dependent and -Independent Paracrine Signaling by Sunitinib-Resistant Renal Cell Carcinoma.
Tran TA; Leong HS; Pavia-Jimenez A; Fedyshyn S; Yang J; Kucejova B; Sivanand S; Spence P; Xie XJ; Peña-Llopis S; Power N; Brugarolas J
Mol Cell Biol; 2016 Jul; 36(13):1836-55. PubMed ID: 27141054
[TBL] [Abstract][Full Text] [Related]
2. Cellular Adaptation to VEGF-Targeted Antiangiogenic Therapy Induces Evasive Resistance by Overproduction of Alternative Endothelial Cell Growth Factors in Renal Cell Carcinoma.
Han KS; Raven PA; Frees S; Gust K; Fazli L; Ettinger S; Hong SJ; Kollmannsberger C; Gleave ME; So AI
Neoplasia; 2015 Nov; 17(11):805-16. PubMed ID: 26678908
[TBL] [Abstract][Full Text] [Related]
3. Adrenomedullin blockade suppresses sunitinib-resistant renal cell carcinoma growth by targeting the ERK/MAPK pathway.
Gao Y; Li J; Qiao N; Meng Q; Zhang M; Wang X; Jia J; Yang S; Qu C; Li W; Wang D
Oncotarget; 2016 Sep; 7(39):63374-63387. PubMed ID: 27556517
[TBL] [Abstract][Full Text] [Related]
4. Autotaxin-lysophosphatidic acid signaling axis mediates tumorigenesis and development of acquired resistance to sunitinib in renal cell carcinoma.
Su SC; Hu X; Kenney PA; Merrill MM; Babaian KN; Zhang XY; Maity T; Yang SF; Lin X; Wood CG
Clin Cancer Res; 2013 Dec; 19(23):6461-72. PubMed ID: 24122794
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma.
Bridgeman VL; Wan E; Foo S; Nathan MR; Welti JC; Frentzas S; Vermeulen PB; Preece N; Springer CJ; Powles T; Nathan PD; Larkin J; Gore M; Vasudev NS; Reynolds AR
Mol Cancer Ther; 2016 Jan; 15(1):172-83. PubMed ID: 26487278
[TBL] [Abstract][Full Text] [Related]
6. Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models.
Ciamporcero E; Miles KM; Adelaiye R; Ramakrishnan S; Shen L; Ku S; Pizzimenti S; Sennino B; Barrera G; Pili R
Mol Cancer Ther; 2015 Jan; 14(1):101-10. PubMed ID: 25381264
[TBL] [Abstract][Full Text] [Related]
7. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.
Huang D; Ding Y; Li Y; Luo WM; Zhang ZF; Snider J; Vandenbeldt K; Qian CN; Teh BT
Cancer Res; 2010 Feb; 70(3):1053-62. PubMed ID: 20103629
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanism mediating cytotoxic activity of axitinib in sunitinib-resistant human renal cell carcinoma cells.
Miyazaki A; Miyake H; Fujisawa M
Clin Transl Oncol; 2016 Sep; 18(9):893-900. PubMed ID: 26597115
[TBL] [Abstract][Full Text] [Related]
9. Importance of fibroblast growth factor receptor in neovascularization and tumor escape from antiangiogenic therapy.
Saylor PJ; Escudier B; Michaelson MD
Clin Genitourin Cancer; 2012 Jun; 10(2):77-83. PubMed ID: 22382009
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration.
Bai L; Yang JC; Ok JH; Mack PC; Kung HJ; Evans CP
Int J Cancer; 2012 Jun; 130(11):2693-702. PubMed ID: 21792888
[TBL] [Abstract][Full Text] [Related]
11. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
12. EMMPRIN promotes angiogenesis, proliferation, invasion and resistance to sunitinib in renal cell carcinoma, and its level predicts patient outcome.
Sato M; Nakai Y; Nakata W; Yoshida T; Hatano K; Kawashima A; Fujita K; Uemura M; Takayama H; Nonomura N
PLoS One; 2013; 8(9):e74313. PubMed ID: 24073208
[TBL] [Abstract][Full Text] [Related]
13. Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts.
Miles KM; Seshadri M; Ciamporcero E; Adelaiye R; Gillard B; Sotomayor P; Attwood K; Shen L; Conroy D; Kuhnert F; Lalani AS; Thurston G; Pili R
PLoS One; 2014; 9(11):e112371. PubMed ID: 25393540
[TBL] [Abstract][Full Text] [Related]
14. A Study of Angiogenesis Markers in Patients with Renal Cell Carcinoma Undergoing Therapy with Sunitinib.
Stubbs C; Bardoli AD; Afshar M; Pirrie S; Miscoria M; Wheeley I; Porfiri E
Anticancer Res; 2017 Jan; 37(1):253-259. PubMed ID: 28011500
[TBL] [Abstract][Full Text] [Related]
15. Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma.
Shibasaki N; Yamasaki T; Kanno T; Arakaki R; Sakamoto H; Utsunomiya N; Inoue T; Tsuruyama T; Nakamura E; Ogawa O; Kamba T
PLoS One; 2015; 10(6):e0130980. PubMed ID: 26114873
[TBL] [Abstract][Full Text] [Related]
16. TGF-beta 1 induces proliferation in human renal fibroblasts via induction of basic fibroblast growth factor (FGF-2).
Strutz F; Zeisberg M; Renziehausen A; Raschke B; Becker V; van Kooten C; Müller G
Kidney Int; 2001 Feb; 59(2):579-92. PubMed ID: 11168939
[TBL] [Abstract][Full Text] [Related]
17. Decreased apoptosis repressor with caspase recruitment domain confers resistance to sunitinib in renal cell carcinoma through alternate angiogenesis pathways.
Gobe GC; Ng KL; Small DM; Vesey DA; Johnson DW; Samaratunga H; Oliver K; Wood S; Barclay JL; Rajandram R; Li L; Morais C
Biochem Biophys Res Commun; 2016 Apr; 473(1):47-53. PubMed ID: 26995091
[TBL] [Abstract][Full Text] [Related]
18. Induction of epithelial-mesenchymal transition via activation of epidermal growth factor receptor contributes to sunitinib resistance in human renal cell carcinoma cell lines.
Mizumoto A; Yamamoto K; Nakayama Y; Takara K; Nakagawa T; Hirano T; Hirai M
J Pharmacol Exp Ther; 2015 Nov; 355(2):152-8. PubMed ID: 26306766
[TBL] [Abstract][Full Text] [Related]
19. Inactivation of endothelial cell phosphoinositide 3-kinase β inhibits tumor angiogenesis and tumor growth.
Azad AK; Zhabyeyev P; Vanhaesebroeck B; Eitzen G; Oudit GY; Moore RB; Murray AG
Oncogene; 2020 Oct; 39(41):6480-6492. PubMed ID: 32879446
[TBL] [Abstract][Full Text] [Related]
20. Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation.
Sakai I; Miyake H; Fujisawa M
BJU Int; 2013 Jul; 112(2):E211-20. PubMed ID: 23305097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
